- Home
- INM vs TOVX Comparison
INM vs TOVX Comparison
Compare INM & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- TOVX
- Stock Information
- Founded
- INM 1981
- TOVX 2001
- Country
- INM Canada
- TOVX United States
- Employees
- INM N/A
- TOVX N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- TOVX Health Care
- Exchange
- INM Nasdaq
- TOVX Nasdaq
- Market Cap
- INM 4.4M
- TOVX 4.5M
- IPO Year
- INM N/A
- TOVX 2006
- Fundamental
- Price
- INM $2.13
- TOVX $0.39
- Analyst Decision
- INM
- TOVX Hold
- Analyst Count
- INM 0
- TOVX 1
- Target Price
- INM N/A
- TOVX N/A
- AVG Volume (30 Days)
- INM 42.3K
- TOVX 1.1M
- Earning Date
- INM 09-29-2025
- TOVX 08-11-2025
- Dividend Yield
- INM N/A
- TOVX N/A
- EPS Growth
- INM N/A
- TOVX N/A
- EPS
- INM N/A
- TOVX N/A
- Revenue
- INM $4,920,990.00
- TOVX N/A
- Revenue This Year
- INM N/A
- TOVX N/A
- Revenue Next Year
- INM N/A
- TOVX N/A
- P/E Ratio
- INM N/A
- TOVX N/A
- Revenue Growth
- INM N/A
- TOVX N/A
- 52 Week Low
- INM $1.72
- TOVX $0.37
- 52 Week High
- INM $8.27
- TOVX $4.97
- Technical
- Relative Strength Index (RSI)
- INM 37.30
- TOVX 37.91
- Support Level
- INM $2.03
- TOVX $0.39
- Resistance Level
- INM $2.25
- TOVX $0.45
- Average True Range (ATR)
- INM 0.08
- TOVX 0.03
- MACD
- INM 0.00
- TOVX -0.00
- Stochastic Oscillator
- INM 34.48
- TOVX 7.39
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.